U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment:: description was created based on several sources, including: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium

Atracurium is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. It is used, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Most adverse reactions were suggestive of histamine release. Common side effects include flushing of the skin and low blood pressure. Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
169.5 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ATRACURIUM BESYLATE

Approved Use

Atracurium Besylate Injection, USP is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Launch Date

8.6918398E11
PubMed

PubMed

TitleDatePubMed
[Interaction of donepezil and muscular blockers in Alzheimer's disease].
2003 Feb
Leaking abdominal aortic aneurysm on anticoagulants-thromboelastography assisted management.
2009 Jun
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Patents

Sample Use Guides

An atracurium besylate dose of 0.4 to 0.5 mg/kg (1.7 to 2.2 times the ED95), given as an intravenous bolus injection, is the recommended initial dose for most patients. Maximum neuromuscular block achieved approximately 3 to 5 minutes after injection.
Route of Administration: Intravenous
In Vitro Use Guide
Exposure of isolated rat hepatocytes to atracurium produced cellular damage evidenced by extrusion of an intracellular enzyme, lactate dehydrogenase (LDH), into the incubation medium. Leakage of LDH was directly related to the concentration of atracurium in the medium (250 to 800 microM). When atracurium was added to the medium and the medium immediately added to hepatocytes, the leakage of LDH increased as the concentration of atracurium increased (P < 0.001 for the comparison with cells not exposed to atracurium).
Substance Class Mixture
Created
by admin
on Sat Jun 26 18:20:29 UTC 2021
Edited
by admin
on Sat Jun 26 18:20:29 UTC 2021
Record UNII
2GQ1IRY63P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ATRACURIUM
VANDF   WHO-DD  
Common Name English
ATRACURIUM CATION
Common Name English
ATRACURIUM [WHO-DD]
Common Name English
ATRACURIUM [VANDF]
Common Name English
2-(2-CARBOXYETHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-1-VERATRYLISOQUINOLINIUM, PENTAMETHYLENE ESTER
Common Name English
ISOQUINOLINIUM, 2,2'-(1,5-PENTANEDIYLBIS(OXY(3-OXO-3,1-PROPANEDIYL)))BIS(1-((3,4-DIMETHOXYPHENYL)METHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL
Common Name English
ATRACURIUM ION
Common Name English
Classification Tree Code System Code
NDF-RT N0000175720
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 20
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
WHO-VATC QM03AC04
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
NCI_THESAURUS C66886
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
WHO-ATC M03AC04
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
NDF-RT N0000175732
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
Code System Code Type Description
FDA UNII
2GQ1IRY63P
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY
MESH
D001279
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY
NCI_THESAURUS
C76068
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY
LACTMED
Atracurium
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY
EVMPD
SUB00618MIG
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY
EPA CompTox
64228-79-1
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY
CAS
64228-79-1
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY
DRUG CENTRAL
259
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY
DRUG BANK
DB00732
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY
RXCUI
1218
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
ATRACURIUM
Created by admin on Sat Jun 26 18:20:30 UTC 2021 , Edited by admin on Sat Jun 26 18:20:30 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Definition References